Macrophage Pharma Appoints Dr Michael Moore as Chairman

11 April 2018, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation small molecules aiming to modulate immune responses to combat cancer and other diseases, announced today that it has appointed Dr. Michael Moore as non-executive Chairman with immediate effect. Commenting on the appointment, Steven Powell, CEO of … Continue reading “Macrophage Pharma Appoints Dr Michael Moore as Chairman”

Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference

7 November 2017, Windsor, UK: Macrophage Pharma Limited (‘MPL’) the immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), announced today that two abstracts will be presented on its proprietary Esterase Sensitive Motif™ (ESM™) technology and its lead development candidate, MPL-5821, a macrophage targeted p38 MAP kinase inhibitor, at the … Continue reading “Macrophage Pharma Limited Presents Data on Lead Immuno-Oncology Programme at 32nd Annual Society for Immunotherapy of Cancer (SITC) Conference”

Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures

Merck Ventures Joins Investment Syndicate and the Board of Macrophage Macrophage Pharma Limited (‘MPL’) the immuno-oncology research and development company focused on macrophage modulation in the tumour microenvironment (TME), announced today that it has raised additional funding from Merck Ventures to complete the Series A Financing announced in January 2017.  Merck Ventures joins the existing … Continue reading “Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures”

Macrophage Pharma Appoints Development Director

Dr Joanne Bedwell-Garner joins management team Macrophage Pharma Limited (‘MPL’) the immuno-oncology development company, announced today that it has appointed Dr Joanne Bedwell-Garner as Development Director. Dr Bedwell-Garner will be responsible for advancing the clinical development of Macrophage Pharma’s lead programme, MPL-5821. This announcement follows the recent £9 million Series A financing, which was led … Continue reading “Macrophage Pharma Appoints Development Director”

Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform

Macrophage Pharma Limited, a newly formed immune-oncology company, today announced that it has successfully raised £9 million in a Series A equity financing round. The Company has also acquired global rights to a novel technology platform, Esterase Sensitive Motif (ESM), from Chroma Therapeutics Limited (Oxford, UK) together with discovery stage therapeutic assets. Macrophage Pharma was … Continue reading “Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform”